Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K

Document




UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549










...

Related Keywords

Frankfurt ,Brandenburg ,Germany ,Netherlands ,Canada ,Washington ,United States ,South Africa ,France ,Australia ,London ,City Of ,United Kingdom ,Italy ,Amsterdam ,Noord Holland ,Japan ,American Samoa ,Italian ,America ,Michael Levitan ,Van Lanschot Kempen ,Lifespring Life Sciences Communication ,Company The ,Bonds ,Commission File Number ,Nasdaq ,Exchange Commission ,Pharming Group ,Linkedin ,Company Euronext Amsterdam ,Vp Investor Relations Corporate Communications ,Frankfurt Stock Exchange ,Pharming Groupnv ,Securities Exchange ,File Number ,Exact Name ,Its Charter ,Regulationst Rule ,Securities Exchange Act ,Sijmen De Vries ,Euronext Amsterdam ,New Bonds ,Maturity Date ,Shareholder Resolution ,Cash Alternative Election ,Long Stop Date ,Fair Bond Value ,Physical Settlement Notice ,Physical Settlement Date ,Open Market ,Issue Date ,Joint Global Coordinators ,Joint Bookrunners ,Lanschot Kempen ,Eligible Bondholders ,Invitation Settlement Date ,Expiration Deadline ,Securities Act ,Joint Dealer Managers ,North America ,Middle East ,Annual Report ,Spring Life Sciences Communication ,Chief Executive Officer ,